* 中国生物科技公司--康方生物9926.HK周二早盘一度升6.5%，早市收高5.6%。
* 该公司此前公告称，中国国家药品监督管理局已于近日批准爱达罗（依若奇单抗）的新药上市申请，用于治疗中度至重度斑块型银屑病成人患者。依若奇单抗是公司自身免疫性疾病领域首个获批上市的一类新药，也是第二个获批上市的非肿瘤新药。
* 康方生物今年迄今劲涨44.2%，同期恒生指数.HSI上扬6.6%。
* 恒生香港上市生物科技指数.HSHKBIO早盘收升4.8%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 张喜良)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.